免疫检查站的安全性抑制剂中国黑色素瘤患者。

StephenW

Melanoma Res. 2016 Jun;26(3):284-289.
Safety of immune checkpoint inhibitors in Chinese patients with melanoma.Wen X1, Wang Y, Ding Y, Li D, Li J, Guo Y, Peng R, Zhao J, Zhang X, Zhang XS.
Author information

• 1State Key Laboratory of Oncology in South China, Biotherapy Center, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  

AbstractThis study aimed to determine the tolerability of Chinese melanoma patients, particularly those with hepatitis B virus (HBV) infection, to immune checkpoint inhibitor therapy. Patients with metastatic melanoma who received anti-cytotoxic T lymphocyte-associated antigen-4 antibody (ipilimumab) or anti-programmed death 1 antibody (pembrolizumab) therapy at our hospital between August 2012 and July 2015 were retrospectively reviewed. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Twenty-three patients with advanced melanoma were included; nine and 10 patients received infusions of ipilimumab and pembrolizumab, respectively, whereas four patients received concurrent ipilimumab and pembrolizumab therapy. There was no cessation of treatment because of agent-related adverse events in any patient. Immune-related adverse events were observed in 44% (4/9), 60% (6/10), 100% (4/4), and 61% (14/23) of patients receiving ipilimumab, pembrolizumab, concomitant ipilimumab and pembrolizumab, and any treatment, respectively. The most frequent immune-related adverse events were endocrine disorders (39%, 9/23), liver function abnormalities (22%, 5/23), and dermatological events (17%, 4/23). There were no gastrointestinal reactions. Toxicities were usually mild and easily managed; only 13% (3/23) of patients had grade 3 adverse events and none experienced grade 4 events or treatment-related death. No additional toxicity nor severe hepatotoxicity was observed in 11 patients who had previous HBV infection. The recommended anti-cytotoxic T lymphocyte-associated antigen-4 and anti-programmed death 1 antibody doses were well tolerated by Chinese patients. Thus, immune checkpoint inhibitors appear to be effective and safe in metastatic melanoma patients, including those with pre-existing HBV infection.

StephenW

黑色素瘤水库。 2016年军; 26（3）：284-289。
免疫检查站的安全性抑制剂中国黑色素瘤患者。
温家宝X1​​，王莹，丁Y，李D，李江，郭Y，彭R，赵Ĵ，张X，XS张。
作者信息肿瘤学国家重点实验室在中国南方，生物治疗中心，中山大学大学癌症中心，协同创新中心的癌症医学，广州，中国的人民共和国。
抽象
这项研究的目的是确定中国黑色素瘤患者的耐受性，特别是那些与乙型肝炎病毒（HBV）感染，免疫检查点抑制剂治疗。转移性黑色素瘤患者谁收到抗细胞毒性T淋巴细胞相关抗原4抗体（易普利姆玛）或抗程序性死亡1抗体（pembrolizumab）疗法在我院2012年8月和2015年7月之间进行回顾性分析。根据美国国家癌症研究所常见术语标准不良事件，3.0版的不良事件进行评估。二十三例晚期黑色素瘤都包括在内;九10例患者分别接受易普利姆玛和pembrolizumab，输注，而四名患者同时接受易普利姆玛和pembrolizumab治疗。没有因为在任何患者剂相关的不良事件的停止治疗。在接收易普利姆玛，pembrolizumab，伴随易普利姆玛的患者的44％（4/9），60％（6/10），100％（4/4），和61％（14/23）观察免疫相关不良事件和pembrolizumab，任何治疗，分别。最常见的免疫相关的不良事件是内分泌紊乱（39％，9/23），肝功能异常（22％，5/23），和皮肤病学事件（17％，4/23）。目前还没有胃肠道反应。不良反应通常是轻微的，易于管理;只有13％的患者（3/23），有3级的不良事件，没有经验的4级事件或治疗相关的死亡。在11例谁以前HBV感染没有观察到毒性的附加也不严重的肝毒性。推荐的抗细胞毒性T淋巴细胞相关抗原4和抗程序性死亡1抗体剂量以及由中国患者的耐受性。因此，免疫检查点抑制剂似乎是在转移性黑色素瘤患者，包括那些与现有的预HBV感染的有效和安全的。